Evidence map›Paper›PMID 39994186›Full record

ArticleCell death & disease2025

Targeting Chk1 and Wee1 kinases enhances radiosensitivity of 2D and 3D head and neck cancer models to X-rays and low/high-LET protons.

Emma Melia, Anne-Sophie Fisch, Ingeborg Tinhofer, Jason L Parsons

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Emma MeliaDepartment of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.ORCID http://orcid.org/0009-0002-1438-0756
Anne-Sophie FischDepartment of Radiooncology and Radiotherapy, Translational Radiation Oncology Research Laboratory, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Ingeborg TinhoferDepartment of Radiooncology and Radiotherapy, Translational Radiation Oncology Research Laboratory, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.ORCID http://orcid.org/0000-0002-0512-549X
Jason L ParsonsDepartment of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK. j.parsons.3@bham.ac.uk.ORCID http://orcid.org/0000-0002-5052-1125

Funding

Realizing the radiobiological impact of protons and high-LET particles in head and neck cancer and glioblastoma modelsR01CA256854 · NCI · UNIVERSITY OF LIVERPOOL · PI PARSONS, JASON · 2021 to 2025
$1.7M
NCI NIH HHS R01 CA256854RCUK | Medical Research Council (MRC) MR/V028944/1U.S. Department of Health & Human Services | National Institutes of Health (NIH) 1R01CA256854
6 · The paper itself

Abstract

Ionising radiation causes the introduction of DNA damage, more specifically double strand breaks (DSBs) and complex DNA damage (CDD), that induces cancer cell death leading to the therapeutic effect. To combat this, cells activate arrest at the G

Indexed as

Cell Cycle ProteinsCheckpoint Kinase 1Head and Neck NeoplasmsProtein-Tyrosine KinasesRadiation ToleranceSquamous Cell Carcinoma of Head and NeckCell Line, TumorG2 Phase Cell Cycle CheckpointsHumansOrganoidsProtein Kinase InhibitorsProton TherapyPyrazolesPyrimidinesPyrimidinonesSpheroids, CellularadavosertibCell Cycle ProteinsCheckpoint Kinase 1CHEK1 protein, humanMK-8776Protein Kinase InhibitorsProtein-Tyrosine KinasesPyrazolesPyrimidinesPyrimidinonesWEE1 protein, human

Identifiers

PMID39994186
PMCPMC11850709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.